Dabrafenib

Dabrafenib Reactions 1704, p129 - 2 Jun 2018 Abducens paresis and decreased cardiac ejection fraction: case report A man in his early 70s [exactage at reaction onset not stated] developed abducens paresis and decreased cardiac ejection fraction during treatment with dabrafenib [route not stated]. The man, who had metastatic stage 4 melanoma, started receiving dabrafenib 150mg twice daily at 66 years of age. He was a part of the BRF113710 trial. He achieved a complete remission after six months. He received treatment for five years. Consequently, his dabrafenib treatment was discontinued after five years of treatment due to decreased cardiac ejection fraction from an initial 60% to 45%. At the time of discontinuation, he was asymptomatic. However, four months later, he developed diplopia which was more significant while looking to his left. A neurological assessment was consistent with abducens (cranial nerve VI) paresis. Additionally, his MRI revealed brain metastasis and he was subsequently diagnosed with meningeal melanomatosis. The man was re-started on dabrafenib 150mg twice daily, along with trametinib. His ejection fraction had not recovered at the time. However, his overall symptoms improved and visual symptoms partially resolved. His ejection fraction did not worsen during the treatment and no additional cardiac toxicity was observed. However, his response was not maintained, and he died 9 months after re-starting dabrafenib. Author comment: "Thus, it cannot be excluded that central nervous system disorder had developed under BRAF inhibitor treatment." "The treatment was withdrawn because of concerns about cardiac toxicity." Gratz V, et al. Meningeal melanomatosis following discontinuation of dabrafenib: Implications for the maintenance of long-term complete remission. Melanoma Research 27: 503-506, No. 5, Oct 2017. Available from: URL: http:// doi.org/10.1097/CMR.0000000000000373 - Germany 803322991 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dabrafenib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/dabrafenib-dKrrJ9I427
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46772-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p129 - 2 Jun 2018 Abducens paresis and decreased cardiac ejection fraction: case report A man in his early 70s [exactage at reaction onset not stated] developed abducens paresis and decreased cardiac ejection fraction during treatment with dabrafenib [route not stated]. The man, who had metastatic stage 4 melanoma, started receiving dabrafenib 150mg twice daily at 66 years of age. He was a part of the BRF113710 trial. He achieved a complete remission after six months. He received treatment for five years. Consequently, his dabrafenib treatment was discontinued after five years of treatment due to decreased cardiac ejection fraction from an initial 60% to 45%. At the time of discontinuation, he was asymptomatic. However, four months later, he developed diplopia which was more significant while looking to his left. A neurological assessment was consistent with abducens (cranial nerve VI) paresis. Additionally, his MRI revealed brain metastasis and he was subsequently diagnosed with meningeal melanomatosis. The man was re-started on dabrafenib 150mg twice daily, along with trametinib. His ejection fraction had not recovered at the time. However, his overall symptoms improved and visual symptoms partially resolved. His ejection fraction did not worsen during the treatment and no additional cardiac toxicity was observed. However, his response was not maintained, and he died 9 months after re-starting dabrafenib. Author comment: "Thus, it cannot be excluded that central nervous system disorder had developed under BRAF inhibitor treatment." "The treatment was withdrawn because of concerns about cardiac toxicity." Gratz V, et al. Meningeal melanomatosis following discontinuation of dabrafenib: Implications for the maintenance of long-term complete remission. Melanoma Research 27: 503-506, No. 5, Oct 2017. Available from: URL: http:// doi.org/10.1097/CMR.0000000000000373 - Germany 803322991 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off